

Neoadjuvant and Adjuvant Treatment in Early-Stage NSCLC: Options Are Expanding – Clinical Brief #1

References

Tweet 2

Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMPOWER010): a randomised, multicentre, open-label, phase 3 trial. *Lancet*. 2021;398:1344-1357. doi:10.1016/S0140-6736(21)02098-5

Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. *N Engl J Med*. 2022;386(21):1973-1985. doi:10.1056/NEJMoa2202170

Jadvar H, Colletti PM, Delgado-Bolton R, et al. Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease. *J Nucl Med*. 2017;58(12):2026-2037. doi:10.2967/jnumed.117.197988

NCCN. Non-small cell lung cancer (Version 5.2022). Accessed October 4, 2022. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Wu Y-L, Tsuboi M, He J, et al., Osimertinib in resected EGFR-mutated non–small-cell lung cancer. *N Engl J Med*. 2020;383:1711-1723. doi:10.1056/NEJMoa2027071

Glossary

Chemo, chemotherapy
CI, confidence interval
DFS, disease-free survival
EFS, event-free survival
ECOG, Eastern Cooperative Oncology Group
EGFR, estimated glomerular filtration rate
HCP, healthcare provider
HR, hazard ratio
N0, no regional lymph node metastasis
NIVO, nivolumab
NSCLC, non-small cell lung cancer
OS, overall survival
PD-L1, programmed death-ligand 1
PFS, progression-free survival
Q3W, every 3 weeks
R0, microscopically complete resection
R, randomized
RT, radiation therapy
TC, tumor cells
TNM, tumor node metastasis
w/, with
YO, years old